Sage Journals: Discover world-class research

Abstract

Practical relevance Feline hypertrophic cardiomyopathy (HCM) is the most common cardiac disease of cats. Treatment of HCM is usually directed at controlling signs of congestive heart failure (CHF), preventing occurrence or recurrence of systemic thromboembolism or delaying/preventing/reversing progression of subclinical disease.

Study objective and design Despite the laudable goals of therapy, however, little objective evidence supporting therapeutic decisions has been published. We, therefore, hypothesized that cardiologists base their treatment strategies on information other than published clinically relevant science. To gain insight into therapeutic decisions that cardiologists and clinicians with an interest in cardiology (n = 99) make for cats with HCM, and on what information they base these decisions, we presented participants with, and asked them to select therapy for, 12 hypothetical scenarios of HCM (± CHF). Responses and justifications for treatment choices were compiled and compared with the results of a comprehensive literature search for published information about treatment of feline HCM.

Findings Evaluation of the therapeutic strategies chosen for these hypothetical cases of HCM suggests that cardiologists or clinicians with a strong interest in cardiology often prescribe treatments knowing that little documented evidence supports their decisions.

Hypertrophic cardiomyopathy (HCM) was first reported as a clinical cardiac condition in cats in the 1970s.¹ Today, HCM is the most common adult-onset cardiac disease in cats, with some estimates of prevalence approaching 20%.^2,3 Sequelae of HCM range from lifelong subclinical disease to sudden death, congestive heart failure (CHF) and cardiogenic aortic thromboembolism (ATE).⁴ Studies of natural history of the disease suggest a median survival in cats initially presenting with subclinical disease of approximately 4 years. This statistic cannot, however, be used to predict the disease course for any individual patient as the rate of progression, severity of disease and potential for the disease to progress are highly variable.^4,5

Despite substantial progress in diagnosis, categorization and etiology of feline HCM,^6–18 little evidence exists regarding efficacy of therapy for HCM at different stages of disease,^19–27 and no therapies for feline HCM have been critically evaluated in large randomized controlled trials.

Commonly described therapies for HCM include diuretics, angiotensin-converting enzyme inhibitors (ACEIs), calcium-channel blockers and beta-blockers.^{4,25,26,28–30} However, most of these have not been rigorously evaluated in cats with HCM. One study suggested no benefit of any therapy other than furosemide, and potential harm of administering β-blockers in cats with CHF secondary to diseases with diastolic dysfunction.³¹ No studies have evaluated the clinical outcomes of treating subclinical HCM in terms of disease progression or survival, although one study found no change in left ventricular wall thickness or diastolic function in Maine Coon cats with subclinical HCM over a 12-month period of ramipril administration.^19,32

HCM is the most common adult-onset cardiac disease in cats, with some estimates of prevalence approaching 20%.

Similarly, no randomized controlled studies have evaluated the outcome of prevention of ATE (either as a first event or recurrence). The Feline Aortic Thromboembolism — Clopidogrel vs Aspirin Trial (FATCAT) is currently evaluating the effect of clopidogrel or aspirin on recurrence of ATE in cats with prior ATE and HCM.³³ Some investigators have examined the ability to reduce dynamic left ventricular outflow tract (LVOT) obstructions in subclinical HCM, although the clinical implications of such interventions have not been defined or examined.^34,35

Thus, demonstrated benefit of most current therapies for HCM in cats is absent from the literature. Under a standard classification system of scientific clinical evidence, most therapy for HCM falls into the lowest category or level of evidence — benchtop science, theoretical benefits and personal observations.³⁶ Nevertheless, review papers, textbook chapters and continuing education presenters often suggest therapies for cats with either sub-clinical or clinical HCM, despite a lack of published evidence of efficacy or safety.^{25,26,28,37–55}

Our hypothesis was that cardiologists do not base their treatment of HCM on credible clinical science that examines patient-oriented outcomes, because such scientific data are lacking. This article collates the published literature evaluating therapy of feline HCM, contrasting this with self-reported treatment strategies chosen for hypothetical cases of HCM by board-certified veterinary cardiologists, cardiology residents and veterinarians with an interest in cardiology.

Materials and methods

Survey of cardiologists

A survey examining treatment strategies for HCM was conducted online in April 2006 through the Veterinary Information Network. A link to the survey was sent via email to 342 members of the American College of Veterinary Internal Medicine (ACVIM) cardiologist listserve. This listserve includes all ACVIM and European College of Veterinary Internal Medicine (ECVIM-CA) certified cardiologists, all UK diplomates in cardiology, all ACVIM and ECVIM cardiology residents and candidates, and approximately 150 veterinarians with an expressed interest in or focus on veterinary cardiology.

Respondents were asked to identify their level of cardiology training (diplomate, post-residency candidate, resident, practitioner with or without interest in feline cardiology, practice limited to cardiology [non-certified], American Board of Veterinary Practitioners [ABVP] certified in feline medicine, UK certificate in cardiology, other).

The survey provided 12 case scenarios of HCM of increasing complexity and severity. Seven scenarios were for cats with subclinical disease and five were for cats with clinical signs. Full details of each scenario are provided in Table 1. For each scenario we asked the clinician to identify therapy that they would prescribe for the ‘typical cat presenting to them with these findings’ to determine ‘standard’ therapeutic decisions.

TABLE 1

Case scenarios for the HCM survey

Scenario Description
Subclinical disease — murmur only	CHF — pulmonary edema and tachypnea/dyspnea
1	Mild symmetrical left ventricular hypertrophy
	No left atrial enlargement
	No systolic anterior motion of the mitral valve or dynamic subaortic stenosis
2	Moderate symmetrical left ventricular hypertrophy
	No left atrial enlargement
	No systolic anterior motion of the mitral valve or dynamic subaortic stenosis
3	Moderate symmetrical left ventricular hypertrophy
	Mild-moderate left atrial enlargement
	Detectable systolic anterior motion of the mitral valve. LVOT velocity 2.2 m/s
4	Moderate symmetrical left ventricular hypertrophy
	Mild-moderate left atrial enlargement
	Detectable systolic anterior motion of the mitral valve. LVOT velocity 4.8 m/s
5	Moderate asymmetrical left ventricular hypertrophy. Marked septal hypertrophy, with subaortic prominence/bulge into LVOT
	Mild-moderate left atrial enlargement
	No systolic anterior motion of the mitral valve or dynamic subaortic stenosis
6	Moderate asymmetrical left ventricular hypertrophy. Marked papillary muscle hypertrophy
	Mild-moderate left atrial enlargement
	Detectable systolic anterior motion of the mitral valve. LVOT velocity 3.8 m/s
7	Severe symmetrical left ventricular hypertrophy
	Severe left atrial enlargement
	Detectable systolic anterior motion of the mitral valve. LVOT velocity 4.5 m/s
8	Severe symmetrical left ventricular hypertrophy
	Severe left atrial enlargement
	No systolic anterior motion of the mitral valve
9	Severe symmetrical left ventricular hypertrophy
	Severe left atrial enlargement
	Detectable systolic anterior motion of the mitral valve. LVOT velocity 2.1 m/s
10	Severe symmetrical left ventricular hypertrophy
	Severe left atrial enlargement
	Detectable systolic anterior motion of the mitral valve. LVOT velocity 4.5 m/s
11	Severe symmetrical left ventricular hypertrophy
	Severe left atrial enlargement
	Detectable left atrial spontaneous echocardiographic contrast (‘smoke’)
12	Severe symmetrical left ventricular hypertrophy
	Severe left atrial enlargement
	Detectable left atrial thrombus

HCM = hypertrophic cardiomyopathy, CHF = congestive heart failure, LVOT = left ventricular outflow tract

Treatment options for each scenario

None

Lasix

ACEI (any kind)

Diltiazem (short- or long-acting)

β-blocker (any kind)

Aspirin

Low-molecular weight heparin

Heparin (unfractionated)

Clopidogrel

Amlodipine

Holistic/alternative

Hospitalization

The web-based survey system randomly assigned respondents to one of two groups (group A or group B) as they began taking the survey. Randomization of the survey was performed using a random-number generator that was coded into the survey system. The case scenarios (Table 1) and treatment options (see box left) provided to each group for each case scenario were identical. In addition to selecting the treatment options they would consider for each case scenario, each respondent was asked to select justification options for their chosen treatments for two of the 12 case scenarios presented (see box on page 489). Group A was asked to provide justification for their therapeutic choices for scenarios 1 and 7, and group B was asked to provide justification for their therapeutic choices for scenarios 4 and 12. We hypothesized that being asked to provide justification for treatment choices would impact the choices made. Randomizing the survey among respondents would allow an unbiased comparison of treatment choices between the two groups.

We did not directly ask whether specific therapeutic interventions were aimed at preventing disease progression or reducing the risk of ATE. However, when non-antithrombotic therapy (ie, furosemide, ACEIs, diltiazem [short or long acting], β-blockers, amlodipine) was selected for scenarios 1–7 (subclinical disease) in any combination, we assumed that this was done in order to affect disease progression (either myocardial remodeling or development of CHF); and when antithrombotic therapy (ie, clopidogrel, aspirin, low molecular weight heparin [LMWH] or unfractionated heparin) was selected for any scenario in any combination, we assumed this was done to reduce the risk of ATE.

Literature search

On March 17, 2006, shortly before releasing the survey to participants, we conducted a literature search on PubMed for published articles related to feline cardiology. We used four different search criteria. First, we compiled a list of all veterinary journals indexed on PubMed. These journal titles were included in the search term as an ‘or’ function. We identified 171 journals that matched ‘veteri^∗’. This journal list was then coupled with two additional search criteria:

All veterinary journals (171) and ‘cats’ [MeSH] and (‘cardiovascular system’ [MeSH] or ‘cardiovascular diseases’ [MeSH]) and (1980 to March 2006).

All veterinary journals (171) and ‘cats’ [MeSH] and (‘cardiol^∗’ or ‘cardiom^∗’ or ‘heart’ or ‘cardio^∗’) and (1980 to March 2006).

Next, we created a search string of all members of the cardiology listserve (author[AU] or …) and substituted the veterinary journals string with the author string (377 authors):

Authors (377) and ‘cats’ [MeSH] and (‘cardiovascular system’ [MeSH] or ‘cardiovascular diseases’ [MeSH]) and (1980 to March 2006).

Authors (377) and ‘cats’ [MeSH] and (‘cardiol^∗’ or ‘cardiom^∗’ or ‘heart’ or ‘cardio^∗’) and (1980 to March 2006).

Additionally, we examined the list for potentially excluded journals and searched those individually using CAB abstracts using the search term ‘hypertrophic cardiomyopathy’.

The search results were combined and duplicates and non-relevant citations were excluded. Excluded citations pertained to hemodynamic effects of anesthetic agents, cardiopulmonary resuscitation, or in vitro experiments utilizing feline myocardium as a model. We then identified all citations related to feline HCM or ATE. These were further classified in three ways. First, we identified the purpose or intent of the article (diagnosis, pathophysiology, anatomy or pathology, treatment or review). Next, we classified those citations addressing treatment according to evidence-based medicine criteria for levels of evidence.³⁶ Finally, we classified the citations as being either ‘disease-oriented outcomes’ or ‘patient-oriented outcomes’.³⁷

Justification options

Justification was sought for treatments selected and treatments not selected

Reasons FOR using

Favorable personal experience

Probably doesn't hurt and might help

Recommendation from specialist consultant or continuing education presenter for use

Consensus of peers for use

Clinical study in cats showing survival or disease progression benefit

Clinical study in other species (including humans) showing survival or disease progression benefit

Research showing physiological response in cats or other species (including humans)

Research suggesting theoretical benefit in cats or other species (including humans)

Textbook recommendation

Reasons FOR NOT using

Unfavorable personal experience

Recommendation from specialist consultant or continuing education presenter against use

Consensus of peers against use

Clinical research showing lack of benefit in cats or other species (including humans)

Clinical research showing adverse outcome in cats or other species (including humans)

No evidence showing benefit with regard to survival or progression in cats

Not a logical choice in this scenario

No experience with this treatment in this condition

Analysis

We performed descriptive analysis of the survey results. We compared use of β-blockers in scenarios where systolic anterior motion of the mitral valve was present versus those where it was not with a Cochran's Q test, which compares proportions for k related samples. Differences were considered significant if P < 0.05.

Most therapy for HCM falls into the lowest category or level of evidence — benchtop science, theoretical benefits and personal observations.

Results

Ninety-eight respondents (29% of listserve) completed the survey (demographics are presented in Table 2). There were no apparent differences in responses between cardiology diplomates and non-diplomates or non-cardiology diplomates. For any given question, at least 88 responses were available for analysis.

TABLE 2

Demographics of survey respondents

Qualification	Group A	Group B
Total	44	54
ACVIM or ECVIM-CA cardiologists	28	32
Cardiology residents	7	13
Other^∗	9	9

∗

UK certificate holders in cardiology or non-cardiology diplomates (eg, internal medicine)

Scenarios 1–7 described patients with sub-clinical disease (murmur but no evidence of CHF or dyspnea/tachypnea). For scenario 1 (extremely mild or equivocal disease), 84% (82/98) of respondents reported that they would not prescribe any pharmacotherapy. Of the 16% (16/98) prescribing medications, all chose ACEIs, diltiazem and/or β-blockers, with 6/16 choosing more than one drug. When presented with scenario 2 (slightly more apparent left ventricular [LV] thickening), 44% (42/96) of respondents indicated that they would prescribe ACEIs, diltiazem and/or β-blockers, and 11 of the 42 chose more than one drug. Approximately 77% (73/95) of respondents stated that they would prescribe one or more drugs by scenario 3 (some left atrial [LA] enlargement and mild dynamic LVOT obstruction): approximately 50% would prescribe β-blockers, 25% an ACEI, 10% diltiazem, and 20% would prescribe aspirin or clopidogrel. Of those prescribing pharmacotherapy at this stage, 47% (33/71) stated that they would prescribe more than one drug. In response to scenario 4 (same as scenario 3 but more severe LVOT obstruction), 90% (83/92) of respondents indicated that they would prescribe pharmacotherapy, with 94% (78/83) of these prescribing a β-blocker. By scenario 7 (severe subclinical disease, with marked LA enlargement and severe LVOT obstruction), 98% (89/91) of respondents indicated that they would administer some sort of therapy, with 84% (75/89) selecting to administer antithrombotic therapy — 66% (59/89) would administer aspirin, and 33% (29/89) would administer clopidogrel or LMWH.

Once CHF was presented as part of the scenario (scenarios 8–12), 100% of respondents stated they would routinely administer furosemide, with or without other therapeutic agents.

Overall, as the complexity of the scenario increased, there was a proportional increase in both the number of respondents stating they would administer some sort of therapy (Fig 1), and the variety of unique responses in terms of therapeutic choices. For example, with scenario 1 (the mildest subclinical scenario presented), respondents formulated seven distinct therapeutic combinations; by scenario 12, respondents formulated 48 distinct therapeutic combinations (Fig 2a). Additionally, as the severity of the disease scenario presented increased, the number of clinicians stating that they would administer three or more medications increased (Fig 2b). In scenarios with CHF, >88% of clinicians stated that they would prescribe three or more medications.

FIG 1

(a) Intent to alter primary disease progression or to treat congestive heart failure (CHF). Collated responses were restricted to drugs or interventions that are not obviously antithrombotic or anticoagulant. (b) Intent to reduce risk of occurrence of aortic thromboembolism (ATE). Collated responses were restricted to clopidogrel, aspirin, low molecular weight heparin (LMWH) and heparin. In (a) and (b) cardiologist respondents are represented by the pink bars, non-cardiologist respondents by the black bars. (c) Use of clopidogrel or LMWH

FIG 2

(a) Number of different treatment combinations adopted by respondents for each scenario. (b) Percentage of respondents prescribing three or more medications to patients with each scenario. CHF = congestive heart failure

Fig 1 shows therapeutic choices based on intervention that we interpreted as being aimed at preventing disease progression (scenarios 1–7; Fig 1a), treating CHF (scenarios 8–12; Fig 1a) or reducing the risk of ATE (all scenarios; Fig 1b). Over 82% (75/91) of respondents showed intent to reduce the risk of ATE by scenario 7, and this approached 98% (86/88) by scenario 12. Fig 1c shows the percentage of respondents selecting LMWH or clopidogrel in each scenario. Clopidogrel therapy was instituted in earlier scenarios, and cardiologists appeared to be more likely than non-cardiologists to prescribe clopidogrel. LMWH use was instituted with severe disease, and selection of LMWH increased with disease severity.

Fig 3 shows use of β-blockers. These drugs were chosen more commonly in subclinical disease when dynamic LVOT obstruction was present (scenarios 3, 4, 6 and 7) (P < 0.0001), and use increased with more severe obstruction — ie, increased use in scenarios 4 (4.8 m/s), 6 (3.8 m/s) and 7 (4.5 m/s) compared with scenario 3 (2.2 m/s) (P < 0.0001). Similarly, with onset of CHF, β-blocker use was chosen more commonly when dynamic LVOT obstruction was present (scenario 9 versus scenario 10) (P < 0.0001). However, fewer clinicians opted to use β-blockers once CHF was present, regardless of the presence or absence of dynamic LVOT obstruction (P < 0.0001).

FIG 3

Cardiologist respondents are represented by the pink bars, non-cardiologist respondents by the black bars. Numbers above bars represent the left ventricular outflow tract (LVOT) velocity (expressed in m/s) associated with LVOT obstruction presented in that particular scenario. CHF = congestive heart failure

Fig 4 shows use of diltiazem and ACEIs. Despite preliminary published evidence of efficacy of diltiazem in treating HCM with CHF,²⁵ only a maximum of 30% of respondents prescribed diltiazem in any scenario (the highest usage was with CHF; Fig 4b). Use appeared to decrease in scenarios with LVOT obstruction. By contrast, ACEI use (Fig 4a) increased steadily with disease complexity, with virtually 100% of respondents using it with CHF.

FIG 4

(a) Angiotensin-converting enzyme inhibitor (ACEI) use increases with increasing severity of hypertrophic cardiomyopathy (HCM). (b) Diltiazem use is substantially lower than ACEI use and is inversely correlated with β-blocker use. Cardiologist respondents are represented by the pink bars, non-cardiologist respondents by the black bars

Table 3 summarizes treatment choices for each scenario.

TABLE 3

Distribution of responses for each scenario in the HCM survey

Scenario	Disease prevention % (n)			ATE risk reduction % (n)			β-blocker use % (n)			Diuretic use % (n)
	Cardio	Other	Total	Cardio	Other	Total	Cardio	Other	Total	Cardio	Other	Total
1	19 (11/59)	13 (5/39)	16 (16/98)	0 (0/59)	0 (0/39)	0 (0/98)	12 (7/59)	3 (1/39)	8 (8/98)	0 (0/59)	0 (0/39)	0 (0/98)
2	45 (26/58)	42 (16/38)	44 (42/96)	0 (0/58)	0 (0/38)	0 (0/96)	26 (15/58)	10 (4/38)	20 (19/96)	0 (0/59)	0 (0/39)	0 (0/98)
3	79 (45/57)	68 (26/38)	75 (71/95)	25 (14/57)	16 (6/38)	21 (30/95)	67 (38/57)	45 (17/38)	58 (55/95)	2 (1/57)	5 (2/38)	3 (3/95)
4	90 (51/57)	91 (32/35)	90 (83/92)	37 (21/57)	29 (10/35)	34 (31/92)	86 (49/57)	83 (29/35)	85 (78/92)	2 (1/57)	3 (1/35)	2 (2/92)
5	74 (43/58)	71 (25/35)	73 (68/93)	31 (18/58)	23 (8/35)	28 (26/93)	48 (28/58)	34 (12/35)	43 (40/93)	2 (1/58)	0 (0/35)	1 (1/93)
6	88 (50/57)	86 (30/35)	87 (80/92)	35 (20/57)	20 (7/35)	29 (27/92)	84 (48/57)	71 (25/35)	79 (73/92)	2 (1/57)	0 (0/39)	1 (1/92)
7	95 (54/57)	94 (32/34)	95 (86/91)	81 (46/57)	85 (29/34)	82 (75/91)	88 (50/57)	74 (25/34)	83 (75/91)	12 (7/57)	18 (6/34)	14 (13/91)
8	NA	NA	NA	86 (48/56)	77 (26/34)	82 (74/90)	18 (10/56)	12 (4/34)	16 (14/90)	100 (56/56)	100 (34/34)	100 (90/90)
8	NA	NA	NA	82 (46/56)	82 (28/34)	82 (74/90)	82 (24/56)	82 (6/34)	82 (30/90)	100 (56/56)	100 (34/34)	100 (90/90)
10	NA	NA	NA	83 (45/54)	82 (28/34)	83 (73/88)	60 (32/54)	35 (12/34)	50 (44/88)	100 (54/54)	100 (34/34)	100 (88/88)
11	NA	NA	NA	98 (54/55)	91 (31/34)	96 (85/89)	22 (12/55)	18 (6/34)	20 (18/89)	100 (55/55)	100 (34/34)	100 (89/89)
12	NA	NA	NA	96 (52/54)	97 (33/34)	97 (85/88)	20 (11/54)	21 (7/34)	21 (18/88)	100 (54/54)	100 (34/34)	100 (88/88)

Scenarios 1–7 described subclinical hypertrophic cardiomyopathy (HCM) patients, scenarios 8–12 described HCM patients with congestive heart failure. See Table 1 for full scenario descriptions. Scenarios 3, 4, 6, 7, 9 and 10 had evidence of dynamic left ventricular outflow tract obstruction. ATE = aortic thromboembolism, NA = not assessed

Justification for therapeutic choices was asked for scenarios 1 and 7 for group A, and scenarios 4 and 12 for group B. Overall, treatment choices by respondents, when asked to justify their decisions, did not differ from the responses by those not asked to justify their decision for any of the scenarios.

For any scenario, the most commonly chosen reasons for not administering a particular therapy were either lack of evidence showing benefit, or that the treatment was not a logical choice in that particular scenario. Reasons chosen to support administering a particular therapy were more varied, but most commonly included research showing theoretical (unproven) benefit in cats or other species, favorable personal experience with a particular therapy, consensus among peers favoring use, or the opinion that the therapy ‘probably doesn't hurt and might help’.

The literature search yielded 540 relevant citations. Of these, 126 addressed issues associated with HCM and 37/126 dealt with therapy of HCM or ATE (20 clinical studies and 17 review articles addressing therapeutic aspects). Of the 20 clinical studies, we identified two randomized clinical trials^23,25 and three prospective case series that addressed patient-oriented outcomes.^22,56,57 We identified three randomized clinical trials addressing disease-oriented outcomes,^19,21,58 eight experimental studies examining aspects of coagulation,^59–66 and four retrospective studies (case-control or case series).^18,22,24,27 We found no published studies addressing use of β-blockers in subclinical HCM. We found no clinical studies examining patient-oriented outcomes (ie, delay of disease progression) in subclinical HCM.

Discussion

Our study highlights the variability of therapeutic approaches to feline HCM of varying severity reported by cardiologists and non-cardiologists. With most of the scenarios presented in this study, there appeared to be marked variability and lack of consensus about most specific therapies. There was general consensus on a few points: all clinicians reported using furosemide with evidence of CHF, most clinicians reported using ACEIs with evidence of CHF, and most clinicians reported using β-blockers with substantial dynamic LVOT obstruction.

With subclinical HCM, treatment choices varied, ranging from mostly no therapy with mild forms of disease, to aggressive therapy with more severe subclinical forms. We assumed in this study that such treatments were aimed at either altering disease progression or preventing ATE, when prescribed to cats with subclinical HCM. Applying this assumption, as the subclinical severity increased, some clinicians displayed a tendency to attempt to delay the onset of CHF by prescribing ACEIs or even diuretics. Similarly, in scenarios where spontaneous left atrial echocardiographic contrast ('smoke’) was present, clinicians displayed an increased tendency to institute antithrombotic therapies, presumably to prevent ATE. We assumed that treatment choices in scenarios describing earlier/milder disease were aimed at altering myocardial remodeling rather than preventing the onset of CHF. Even with the mildest disease, a small proportion of clinicians reported that they would administer some form of therapy.

Treatment decisions made by veterinary cardiologists did not appear to differ dramatically from those made by veterinarians with an interest in cardiology. Our findings show a marked disconnect between published clinical data for therapy of cats with HCM and treatment choices made by cardiologists and non-cardiologists when treating both clinical and subclinical HCM.

Despite the willingness of cardiologists to adopt treatment strategies for their feline HCM patients, we could find virtually no clinically relevant literature to support these decisions …

Despite the willingness of cardiologists to adopt treatment strategies for their feline HCM patients, we could find virtually no clinically relevant literature to support these decisions. This issue was recognized by the survey participants when asked to justify their choices — they rarely selected the justification option that a particular therapy had been demonstrated by controlled clinical trials to have a clinical benefit in the scenario in which they were prescribing the medication. Previous authors have made similar observations about the paucity of therapeutic evidence.^29,67 In most cases, clinicians prescribed medications because of theoretical benefits, extrapolations from human HCM therapy, peer consensus, or because it ‘probably doesn't hurt and might help’ (however, as was pointed out to one of the authors by a colleague, this is merely the optimist's version of ‘probably doesn't help and might hurt’!).

The reasons for this disconnect between sufficient clinical evidence for instituting therapy and self-reported treatment strategies are likely multifactorial. These include personal favorable experience (as with β-blocker use for dynamic LVOT obstruction); the desire by clinicians to ‘do something’; pressure from clients or referring veterinarians to provide a service beyond diagnosis (to offset the feeling of futility or frustration in the client or clinician); and belief that their intervention is, at worst, doing nothing and, at best, altering disease outcome.

… In most cases, clinicians prescribed medications because of theoretical benefits, extrapolations from human HCM therapy, peer consensus, or because it ‘probably doesn't hurt and might help’.

In other cases, the treatment alters a measurable physiological variable, such as LVOT obstruction. Clinicians likely used this as a surrogate marker of clinical outcomes, despite a lack of evidence demonstrating such relationships. Additionally, clinicians commonly justified their use of certain drugs by extrapolating from data in other species. This was most apparent for β-blocker therapy of LVOT obstruction (where treatment of humans provides symptomatic relief and improves exercise tolerance) and use of anticoagulants (LMWH and clopidogrel). However, the problems with such approaches (personal experience, interspecies extrapolation) are highlighted by one investigator, who, in a review of β-blockade in HCM in 1991, suggested that clinical experience and extrapolation from other species would support the use of β-blockers in cats with CHF secondary to HCM.²⁶ This same investigator subsequently failed to demonstrate this benefit in a clinical study, and showed potential harm of such therapy.³¹

Of note is the reported common practice of prescribing medications for treating subclinical HCM. We assumed this practice was based on the hypothesis that early intervention would result in slowed disease progression. Almost 50% of clinicians adopted this strategy with mild disease, and almost all adopted this strategy with severe subclinical disease, despite the lack of evidence demonstrating any benefit of therapy in subclinical HCM in cats. Our findings also demonstrated that as the complexity of the disease increased, the tendency to prescribe three or more drugs increased, with 88% of clinicians prescribing three or more drugs at the onset of CHF. This observation raises several points for consideration (see box below):

Clinicians should consider the potential negative implications of committing a client and patient to potentially prolonged therapy that often requires more-than-once-daily administration of multiple medications.

Recently, investigators examined factors that impacted quality of life decisions for owners of cats with heart failure and found that owner stress of administering medications increased with the number and frequency of medications.⁷² Thus, clinicians should consider the potential negative implications of their treatment strategies when committing a client and patient to potentially prolonged therapy that often requires more-than-once-daily administration of multiple medications.

We were surprised by the infrequent use of diltiazem in feline HCM. When asked to justify their choice for not using diltiazem in the four scenarios requesting justification, approximately 50% of respondents stated that they did not use it because there was ‘no evidence showing benefit with regard to survival or progression in cats’. Thus, it appears that a preliminary study suggesting benefit in cats with HCM and CHF has not translated, for most clinicians, into experience of clinical benefit.²⁵ There appeared to be an inverse relationship between β-blocker use and diltiazem use for individual scenarios. In the cases with dynamic LVOT obstruction, diltiazem use decreased, presumably because of the concerns of using β-blockers and diltiazem together.

Treatment of subclinical HCM: considerations

Given the unpredictable nature of HCM in most cats, with no clear means of distinguishing early progressive disease from mild, non-progressive disease, it is highly likely that many feline patients are subjected to unnecessary medical therapy, because the disease in these patients would never progress, regardless of intervention.

Given the lack of evidence for benefit, medicating may subject many patients and clients to years of unnecessary inconvenience and stress.

Given that clients might not observe a benefit (as the cat has subclinical disease) and/or experience difficulty medicating their cat, especially when administering three or more medications, non-compliance rate might be substantially higher than specialist clinicians suspect. This can lead to an over-estimation of benefits of therapy. Additionally, clients not willing to admit to non-compliance might elect not to present their patients for follow-up visits or elect to follow-up with other clinicians to avoid embarrassment or conflict with the prescribing veterinarian. This could result in suboptimal management of cases or a presumption by the clinician that ‘all is well’ with the patient and that their therapy was of benefit.

Given that no data exist about clinically relevant outcomes of the therapies commonly employed with subclinical HCM (as reported in this study), there is an unfounded assumption that therapy is either helping, or doing no harm. It is, however, quite possible, as previous landmark studies in human medicine have demonstrated, that perceived and commonly acknowledged ‘benefits’ of therapies can indeed be harmful, when critically evaluated.^68–71

Limitations

This study has a number of limitations. Several clinicians alluded to the fact that they tailor therapy to the specific individual. However, we were interested in ‘average’ treatment choices in each scenario — what a clinician was likely to do given a set of observations in a cat with HCM.

Additionally, we presented somewhat loose definitions of severity based on left atrial size and wall thickness, which we labelled as ‘mild’, ‘moderate’ and ‘severe’. Respondents could interpret these classifications differently, or use the various criteria differently (eg, left atrial enlargement versus wall thickness) to determine treatment choices. How this would affect the survey results is unclear.

We did not specifically ask for the clinicians' intent as to their therapeutic choices, but made assumptions about intent based on the known pharmacology of the drugs chosen and standard therapeutic strategies adopted with these drugs. Therefore, it is possible that, in some cases, our assumptions were incorrect and that respondents were prescribing medications for reasons other than those which we ascribed.

Our literature search was possibly not exhaustive. However, we believe that we identified all the literature pertinent to treatment of feline HCM that had been published during the specified period. Subsequent to the original search, a few additional studies have been published detailing aspects of treatment and pathophysiology of HCM, but we do not believe that they have impacted the therapeutic decisions of cardiologists (as evidenced in a recent unpublished survey of veterinary cardiologists).^20,73,74

Footnotes

Acknowledgements

We would like to thank Cornell reference librarian Susanne Whitaker for help with the literature search. The data in this article were first presented as an abstract at the ECVIM-CA Congress, Amsterdam, September 14–16, 2006.

References

1. Liu

Tilley

Lord

. Feline cardiomyopathy. Recent Adv Stud Cardiac Struct Metab 1975; 10: 627–40.

2. Paige

Abbott

Elvinger

Pyle

. Prevalence of cardiomyopathy in apparently healthy cats. J Am Vet Med Assoc 2009; 234: 1398–403.

3. Coté

Manning

Emerson

Laste

Malakoff

Harpster

. Assessment of the prevalence of heart murmurs in overtly healthy cats. J Am Vet Med Assoc 2004; 225: 384–88.

4. Rush

Freeman

Fenollosa

Brown

. Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990–1999). J Am Vet Med Assoc 2002; 220: 202–7.

5. Atkins

Gallo

Kurzman

Cowen

. Risk factors, clinical signs, and survival in cats with a clinical diagnosis of idiopathic hypertrophic cardiomyopathy: 74 cases (1985–1989). J Am Vet Med Assoc 1992; 201: 613–18.

6. Fox

Liu

Maron

. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. Circulation 1995; 92: 2645–51.

7. Meurs

Sanchez

David

, et al. A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy. Hum Mol Genet 2005; 14: 3587–93.

8. Meurs

Norgard

Ederer

Hendrix

Kittleson

. A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy. Genomics 2007; 90: 261–64.

9. Carlos Sampedrano

Chetboul

Gouni

Nicolle

Pouchelon

Tissier

. Systolic and diastolic myocardial dysfunction in cats with hypertrophic cardiomyopathy or systemic hypertension. J Vet Intern Med 2006; 20: 1106–15.

10.

10. Carlos Sampedrano

Chetboul

Mary

, et al. Prospective echocardiographic and tissue Doppler imaging screening of a population of Maine Coon cats tested for the A31P mutation in the myosin-binding protein C gene: a specific analysis of the heterozygous status. J Vet Intern Med 2009; 23: 91–99.

11.

11. Adin

Diley-Poston

. Papillary muscle measurements in cats with normal echocardiograms and cats with concentric left ventricular hypertrophy. J Vet Intern Med 2007; 21: 737–41.

12.

12. MacDonald

Kittleson

Garcia-Nolen

Larson

Wisner

. Tissue Doppler imaging and gradient echo cardiac magnetic resonance imaging in normal cats and cats with hypertrophic cardiomyopathy. J Vet Intern Med 2006; 20: 627–34.

13.

13. MacDonald

Kittleson

Kass

Meurs

. Tissue Doppler imaging in Maine Coon cats with a mutation of myosin binding protein C with or without hypertrophy. J Vet Intern Med 2007; 21: 232–37.

14.

14. Koffas

Dukes McEwan

Corcoran

, et al. Pulsed tissue Doppler imaging in normal cats and cats with hypertrophic cardiomyopathy. J Vet Intern Med 2006; 20: 65–77.

15.

15. Schober

Maerz

. Assessment of left atrial appendage flow velocity and its relation to spontaneous echocardiographic contrast in 89 cats with myocardial disease. J Vet Intern Med 2006; 20: 120–30.

16.

16. Cesta

Baty

Keene

Smoak

Malarkey

. Pathology of end-stage remodeling in a family of cats with hypertrophic cardiomyopathy. Vet Pathol 2005; 42: 458–67.

17.

17. Ferasin

Sturgess

Cannon

Caney

Gruffydd-Jones

Wotton

. Feline idiopathic cardiomyopathy: a retrospective study of 106 cats (1994–2001). J Feline Med Surg 2003; 5: 151–59.

18.

18. Laste

Harpster

. A retrospective study of 100 cases of feline distal aortic thromboembolism: 1977–1993. J Am Anim Hosp Assoc 1995; 31: 492–500.

19.

19. MacDonald

Kittleson

Larson

Kass

Klose

Wisner

. The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure. J Vet Intern Med 2006; 20: 1093–105.

20.

20. MacDonald

Kittleson

Kass

White

. Effect of spironolactone on diastolic function and left ventricular mass in Maine Coon cats with familial hypertrophic cardiomyopathy. J Vet Intern Med 2008; 22: 335–41.

21.

21. Taillefer

Di Fruscia

. Benazepril and sub-clinical feline hypertrophic cardiomyopathy: a prospective, blinded, controlled study. Can Vet J 2006; 47: 437–45.

22.

22. Smith

Tobias

Jacob

Fine

Grumbles

. Arterial thromboembolism in cats: acute crisis in 127 cases (1992–2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med 2003; 17: 73–83.

23.

23. Amberger

Glardon

Glaus

, et al. Effects of benazepril in the treatment of feline hypertrophic cardiomyopathy: results of a prospective, open-label, multicenter clinical trial. J Vet Cardiol 1999; 1: 19–26.

24.

24. Rush

Freeman

Brown

Smith

Jr . The use of enalapril in the treatment of feline hypertrophic cardiomyopathy. J Am Anim Hosp Assoc 1998; 34: 38–41.

25.

25. Bright

Golden

Gompf

Walker

Toal

. Evaluation of the calcium channel-blocking agents diltiazem and verapamil for treatment of feline hypertrophic cardiomyopathy. J Vet Intern Med 1991; 5: 272–82.

26.

26. Fox

. Evidence for or against efficacy of beta-blockers and aspirin for management of feline cardiomyopathies. Vet Clin North Am Small Anim Pract 1991; 21: 1011–22.

27.

27. Smith

Rozanski

Freeman

Brown

Goodman

Rush

. Use of low molecular weight heparin in cats: 57 cases (1999–2003). J Am Vet Med Assoc 2004; 225: 1237–41.

28.

28. Baty

. Feline hypertrophic cardiomyopathy: an update. Vet Clin North Am Small Anim Pract 2004; 34: 1227–34.

29.

29. Ferasin

. Feline myocardial disease 2: diagnosis, prognosis and clinical management. J Feline Med Surg 2009; 11: 183–94.

30.

30. Watson

Church

. Preferences of veterinarians for drugs to treat heart disease in dogs and cats. Aust Vet J 1995; 72: 401–3.

31.

31. Fox

. Prospective, double-blinded, multicenter evaluation of chronic therapies for feline diastolic heart failure: interim analysis. Proceedings of the American College of Veterinary Internal Medicine; June 6–9, 2003; Charlotte, NC. http://beta.vin.com/Members/Proceedings/Proceedings.plx?CID&acvim2003&PID=pr04461&O=VIN (accessed Dec 8, 2010).

32.

32. MacDonald

Kittleson

Larson

Kass

Klose

Wisner

33.

33. Hogan

. Update from the FAT CAT study on arterial thromboembolism. Proceedings of the American College of Veterinary Internal Medicine; June 4–7, 2008; San Antonio. http://beta.vin.com/Members/Proceedings/Proceedings.plx?CID&acvim2008&PID=pr22820&O=VIN (accessed Dec 8, 2010).

34.

34. Lamont

Bulmer

Sisson

Grimm

Tranquilli

. Doppler echocardiographic effects of medetomidine on dynamic left ventricular outflow tract obstruction in cats. J Am Vet Med Assoc 2002; 221: 1276–81.

35.

35. Wey

Kittleson

. Comparison of the efficacy of intravenous diltiazem and esmolol to reduce left ventricular outflow tract velocity and heart rate in cats with hypertrophic obstructive cardiomyopathy. J Vet Intern Med 2000; 14: 335.

36.

36. Cockcroft

Holmes

. Handbook of evidence-based veterinary medicine. Oxford, UK: Blackwell, 2003.

37.

37. Bright

Golden

. Evidence for or against the efficacy of calcium channel blockers for management of hypertrophic cardiomyopathy in cats. Vet Clin North Am Small Anim Pract 1991; 21: 1023–34.

38.

38. Mendinger

Bruyette

. Feline hypertrophic cardiomyopathy. Compend Contin Educ Pract Vet 1992; 14: 479–83, 486–88, 490–92.

39.

39. Gruffydd Jones

Wotton

. Cardiomyopathy and thromboembolism in cats. Vet Annu 1986; 26: 348–60.

40.

40. Freeman

. Nutritional management of feline heart disease. NAVC Clinician's Brief 2004; 15–17, 79.

41.

41. Smith

Tobias

. Feline arterial thromboembolism: an update. Vet Clin North Am Small Anim Pract 2004; 34: 1245–71.

42.

42. Dunn

. Hypertrophic cardiomyopathy. VN Times 2004; 4: 14.

43.

43. Falconer

Atwell

. Feline aortic thromboembolism. Aust Vet Pract 2003; 33: 20–32.

44.

44. Falconer

Atwell

. Haemostasis, anticoagulation and feline aortic thromboembolism. Aust Vet Pract 2003; 33: 160–71.

45.

45. Fuentes

. Diastolic function — is this the key to successful management of many feline cardiomyopathies? J Feline Med Surg 2003; 5: 51–56.

46.

46. Fuentes

. Feline heart disease: an update. J Small Anim Pract 1992; 33: 130–37.

47.

47. Behrend

Grauer

Greco

. Feline hypertrophic cardiomyopathy, Part 1. Feline Pract 1996; 24: 34–37.

48.

48. Behrend

Grauer

Greco

. Feline hypertrophic cardiomyopathy. Part 3. Feline Pract 1997; 25: 22–25.

49.

49. Behrend

Grauer

Greco

. Feline hypertrophic cardiomyopathy, Part 2. Feline Pract 1997; 25: 9–12.

50.

50. Atkins

. Feline cardiomyopathy. Publication Veterinary Continuing Education, Massey University, 1995; 33–41.

51.

51. Rodriguez

Harpster

. Treatment of feline hypertrophic cardiomyopathy. Compend Contin Educ Pract Vet 2002; 24: 470–75.

52.

52. Haggstrom

. Hypertrophic cardiomyopathy in cats — it used to be so simple! J Feline Med Surg 2003; 5: 139–41.

53.

53. Bonagura

. Feline hypertrophic cardiomyopathy. Vet Q 1997; 19: s5–s6.

54.

54. Rush

. Therapy of feline hypertrophic cardiomyopathy. Vet Clin North Am Small Anim Pract 1998; 28: 1459–79, ix.

55.

55. Labuc

. Cardiomyopathy in the dog and cat — part II. Publication Veterinary Continuing Education, Massey University 1996; 137–46.

56.

56. Pion

. Feline aortic thromboemboli and the potential utility of thrombolytic therapy with tissue plasminogen activator. Vet Clin North Am Small Anim Pract 1988; 18: 79–86.

57.

57. Reimer

Kittleson

Kyles

. Use of rheolytic thrombectomy in the treatment of feline distal aortic thromboembolism. J Vet Intern Med 2006; 20: 290–96.

58.

58. Freeman

Brown

Smith

Rush

. Magnesium status and the effect of magnesium supplementation in feline hypertrophic cardiomyopathy. Can J Vet Res 1997; 61: 227–31.

59.

59. Schaub

Gates

Roberts

. Effect of aspirin on collateral blood flow after experimental thrombosis of the feline aorta. Am J Vet Res 1982; 43: 1647–50.

60.

60. Bright

Dowers

Powers

. Effects of the glycoprotein IIb/IIIa antagonist abciximab on thrombus formation and platelet function in cats with arterial injury. Vet Ther 2003; 4: 35–46.

61.

61. Killingsworth

Eyster

Adams

Bartlett

Bell

. Streptokinase treatment of cats with experimentally induced aortic thrombosis. Am J Vet Res 2086; 47: 1351–59.

62.

62. Behrend

Grauer

Greco

Rose

Thrall

MAH

. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc 1996; 32: 11–18.

63.

63. Hogan

Andrews

Green

Talbott

Ward

Calloway

. Antiplatelet effects and pharmacodynamics of clopidogrel in cats. J Am Vet Med Assoc 2004; 225: 1406–11.

64.

64. Hogan

Ward

. Effect of clopidogrel on tissue-plasminogen activator-induced in vitro thrombolysis of feline whole blood thrombi. Am J Vet Res 2004; 65: 715–19.

65.

65. Hogan

Andrews

Talbott

Green

Ward

Calloway

. Evaluation of antiplatelet effects of ticlopidine in cats. Am J Vet Res 2004; 65: 327–32.

66.

66. Bright

Sullivan

Melton

Schneider

McDonald

. The effects of n-3 fatty acid supplementation on bleeding time, plasma fatty acid composition, and in vitro platelet aggregation in cats. J Vet Intern Med 1994; 8: 247–52.

67.

67. Abbott

. Feline hypertrophic cardiomyopathy: an update. Vet Clin North Am Small Anim Pract 2010; 40: 685–700.

68.

68. Echt

Liebson

Mitchell

, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med 1991; 324: 781–88.

69.

69. Patterson

Fetzer

Krall

Wright

Heller

. Eye patch treatment for the pain of corneal abrasion. South Med J 1996; 89: 227–29.

70.

70. Le Sage

Verreault

Rochette

. Efficacy of eye patching for traumatic corneal abrasions: a controlled clinical trial. Ann Emerg Med 2001; 38: 129–34.

71.

71. Gilbert

Salanti

Harden

See

. Infant sleeping position and the sudden infant death syndrome: systematic review of observational studies and historical review of recommendations from 1940 to 2002. Int J Epidemiol 2005; 34: 874–87.

72.

72. Reynolds

Oyama

Rush

, et al. Perceptions of quality of life and priorities of owners of cats with heart disease. J Vet Intern Med 2010; 24: 1421–26.

73.

73. Jandrey

Norris

MacDonald

Kittleson

Tablin

. Platelet function in clinically healthy cats and cats with hypertrophic cardiomyopathy: analysis using the Platelet Function Analyzer-100. Vet Clin Pathol 2008; 37: 385–88.

74.

74. Stokol

Brooks

Rush

, et al. Hypercoagulability in cats with cardiomyopathy. J Vet Intern Med 2008; 22: 546–52.

Is Treatment of Feline Hypertrophic Cardiomyopathy Based in Science or Faith?

Abstract

Materials and methods

Survey of cardiologists

Treatment options for each scenario

Literature search

Justification options

Justification was sought for treatments selected and treatments not selected

Reasons FOR using

Reasons FOR NOT using

Analysis

Results

Discussion

Treatment of subclinical HCM: considerations

Limitations

Footnotes

Acknowledgements

References